Oruka Therapeutics, Inc. Repayments of Short-term Debt, Maturing in More than Three Months
Oruka Therapeutics, Inc. (ORKA) reported Repayments of Short-term Debt, Maturing in More than Three Months of $408.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths · last filed 2022-03-14
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for the quarter ending 2020-12-31 was $137.00K, a 16.10% increase year-over-year.
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for the quarter ending 2020-09-30 was $136.00K, a 18.26% increase year-over-year.
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for the quarter ending 2019-12-31 was $118.00K, a 12.38% increase year-over-year.
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for the quarter ending 2019-09-30 was $115.00K.
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for fiscal 2020 was $408.00K, a 16.91% increase from fiscal 2019.
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for fiscal 2019 was $349.00K, a 12.22% increase from fiscal 2018.
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for fiscal 2018 was $311.00K, a 21.48% increase from fiscal 2017.
- Oruka Therapeutics, Inc. repayments of short-term debt, maturing in more than three months for fiscal 2017 was $256.00K.
| Period end | Repayments of Short-term Debt, Maturing in More than Three Months 3 month | Repayments of Short-term Debt, Maturing in More than Three Months 6 month | Repayments of Short-term Debt, Maturing in More than Three Months 9 month | Repayments of Short-term Debt, Maturing in More than Three Months 12 month |
|---|---|---|---|---|
| 2020-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $273.00K derived: sum of 2 quarters · filed 2022-03-14 | $408.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $271.00K 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $135.00K 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $233.00K derived: sum of 2 quarters · filed 2021-03-18 | $349.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $231.00K 10-Q · filed 2020-11-02 | ||
| 2019-06-30 | $116.00K 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-18 | $105.00K derived: sum of 2 quarters · filed 2020-02-18 | $311.00K 10-K · filed 2020-02-18 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $206.00K 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $206.00K 10-Q · filed 2019-08-01 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $86.00K derived: sum of 2 quarters · filed 2019-02-27 | $256.00K 10-K · filed 2019-02-27 | |
| 2017-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $256.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $170.00K 10-Q · filed 2018-08-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $55.00K derived: sum of 2 quarters · filed 2017-03-21 | $138.00K derived: sum of 3 quarters · filed 2017-03-21 | $193.00K 10-K · filed 2017-03-21 |
| 2015-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $138.00K derived: sum of 2 quarters · filed 2016-11-14 | $193.00K 10-Q · filed 2016-11-14 | $193.00K derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $138.00K 10-Q · filed 2016-08-09 | $138.00K derived: sum of 3 quarters · filed 2016-08-09 | $189.00K derived: sum of 4 quarters · filed 2016-08-09 |
| 2015-03-31 | $55.00K 10-Q · filed 2016-05-11 | $55.00K derived: sum of 2 quarters · filed 2016-05-11 | $106.00K derived: sum of 3 quarters · filed 2016-05-11 | $183.00K derived: sum of 4 quarters · filed 2016-05-11 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-17 | $51.00K derived: sum of 2 quarters · filed 2016-03-17 | $128.00K derived: sum of 3 quarters · filed 2016-03-17 | $179.00K 10-K · filed 2016-03-17 |
| 2014-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $128.00K derived: sum of 2 quarters · filed 2015-11-12 | $179.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $77.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $128.00K 10-Q · filed 2015-08-11 | ||
| 2014-03-31 | $51.00K 10-Q · filed 2015-05-12 | |||
| 2013-12-31 | $174.00K 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |